In2Pharma
  • Home
  • Services
    • Regulatory Affairs
    • Quality Assurance
    • Publicity and Compliance
    • Medical writing & training
    • Vigilance
  • About Us
  • News
  • Contact
Select Page

EU rules for batch testing of medicinal products after BREXIT

by In2Pharma | Feb 28, 2019 | News

European Union In light of the withdrawal of the United Kingdom from the European Union, the European Commission has published a letter on the rules for batch testing of medicinal products after the Brexit. The competent authorities may allow marketing authorisation...

PRAC recommendations on fluoroquinolone and quinolone antibiotics

by In2Pharma | Dec 18, 2018 | News

EMA Following a review of disabling and potential long-term side effects of fluoroquinolone and quinolone antibiotics, the Pharmacovigilance Risk Assessment Committee (PRAC) has recommended a restriction of the use of these products. It concerns fluoroquinolone and...

Recent Posts

  • Update Belgian FAQ on nutrition and health claims
  • Simplification of disclaimers for promotional materials
  • REACH Microplastics Restriction: What You Need to Know – and Do – Today!
  • “Successive GMP certificate” applications
  • New contact form for questions on variations and renewals from 1 June 2025

Follow Us

  • Facebook
  • LinkedIn
Privacy Policy | Cookie Policy | BTW BE 895730662 | +32 16 89 16 00| info@in2pharma.com | Terloonststraat 22, 1910 Kampenhout, België